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A B S T R A C T
Non-melanoma skin cancers (NMSC) are the most common malignant tumors in white population and their inci-
dence has been increasing worldwide. Molecular events regulating cell survival, apoptosis, growth arrest as well as cell
differentiation, are important contributors to the overall kinetics of benign and malignant cell growth and play a role in
their development, progression and regression. Failure of these pathways can result in the loss of control over prolifera-
tion and lead to tumor development through the inactivation of tumor suppressor genes or the activation of oncogenes.
Also, immunological mechanisms have been implicated in a phenomenon of tumor progression as well as spontaneous
tumor regression. We have tried to summarize the main events in etiopatogenesis, development, progression and in some
cases skin cancer regression. Further studies are needed to elucidate completely the details of apoptotic control in normal
skin and determine factors resulting in apoptotic disbalance and disease.
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Introduction
Skin tumors include malignant melanomas and non-
melanoma cancers (NMSCs) that are neoplasms of epi-
thelial origin such as basal cell carcinoma (BCC), kerato-
acanthoma (KA) and squamous cell carcinoma (SCC).
NMSC are the most common malignant tumors in white
population and incidence has been increasing at an as-
tonishing rate over the past several decades worldwide1.
Hundred years after its initial description, there is much
controversy in the literature regarding whether KA is to
be considered a variant of well-differentiated SCC or a
separate entity2. In contrast to KA initial intensive
growth and tendency to regress, SCC is characterized by
locally destructive growth and tendency to metastases2.
Occasionally, otherwise typical KA characterized by ini-
tial intensive growth and usually spontaneous regres-
sion, can behave aggressively showing the signs of peri-
neural and perivascular invasion and form metastases in
regional lymph nodes2. The most important feature that
separates KA from SCC is a tendency of KA to regress
but causes and detailed mechanism of this regression are
still not completely elucidated.
It has become clear that molecular events regulating
cell survival, apoptosis, growth arrest as well as cell dif-
ferentiation, are important contributors to the overall ki-
netics of benign and malignant cell growth and play a
role in development, progression and regression of be-
nign and malignant cell growth3,4. Failure of these path-
ways can result in the loss of control over proliferation
and lead to tumor development through the inactivation
of tumor suppressor genes or the activation of oncogenes.
Also, immunological mechanisms have been implicated
in a phenomenon of tumor progression as well as sponta-
neous tumor regression5,6.
UV Irradiation in Epidemiology of
Non-Melanoma Skin Cancer
Ultraviolet (UV) irradiation can be both beneficial
and harmful to normal human skin. The most important
harmful effects of UV irradiation are immune suppres-
sion, photoaging and, the most importantly, skin carcino-
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genesis. It is well known that skin tumors result from
co-carcinogenic effect of different factors such as UV
light, irradiation, chemical carcinogens, genetic factors
and oncogenic viruses2,7–9. Interaction of these factors
with genetic predisposition in a certain individual can
lead to skin cancer development.
Recent developments in molecular biology and re-
search on laboratory animals have determined a central
role of UV irradiation in the pathogenesis of NMSC. Ma-
jority of NMSC, 90% of SCCs2,8,10, 85–90% of KAs11 and
80% of BCCs12, occur on sun-exposed skin. It is clear that
wavelengths in UVB region of the solar spectrum are ab-
sorbed in the skin producing erythema, burns and even-
tually skin cancer. By contrast, UVA region cause not
only ageing and wrinkling of the skin, but also skin can-
cer when given in high doses over a long period of time13.
UVA, which is less potent than UVB, can trigger apo-
ptosis through oxidative damage14. On the other hand,
UVC as a more potent apoptotic stimulator than UVB
and can damage cellular DNA, it is largely absorbed in
the atmosphere and does not reach the Earth’s surface.
UV irradiation in UVB region from 245 to 290 nm is
maximally absorbed by DNA inducing mutagenic photo-
products or lesions in DNA between adjacent pyrimidine
residues in the form of dimmers10. If not repaired, UV-in-
duced DNA lesions can lead to mutations in the DNA
sequences10. These mutations are in the form of C to T
and CC to TT transitions, known as UV »signature« mu-
tations.
DNA Repair Mechanisms
Cells are equipped with several DNA repair systems
that are able to protect the cell from the effects of
DNA-damage factors. These pathways include photo-
reactivation, base excision repair, mismatch repair, dou-
ble-stranded break repair and nucleotide excision repair
(NER) that removes bulky DNA damage. UV-induced
DNA damage is primarily repaired by NER. Defects in
NER can lead to three distinct human diseases: xero-
derma pigmentosum, Cockayne syndrom and trichothio-
dystrophy; among these xeroderma pignentosum pa-
tients exhibit predisposition to skin cancer and photo-
sensitivity15. These patients have a more than 1000-fold
increased risk of skin cancer. Basal and squamous cell
carcinomas and less frequently melanomas appear al-
most exclusively in sun-exposed areas.
Major Pathways of Apoptosis
Apoptosis is active, genetically controlled process of
programmed cell death leading to cell destruction with
no involvement of surrounding cells or inflammatory
response16,17. The balance between apoptosis, prolifera-
tion and differentiation is responsible for maintaining of
tissue homeostasis, also keratinocyte differentiation is
considered a type of apoptosis16,17. Alterations in apo-
ptotic process have been implicated in many skin disea-
ses16,17.
Bcl-2 family proteins play a central role in controlling
the intrinsic pathway, triggered by most cytotoxic drugs
and DNA damage, which involves mitochondrial release
of cytochrome c, which combines with the cofactor
Apaf-1 (ced-4 homoloque) in the formation of activated
caspase-9 »apoptosome«. Mitochondria may also promote
apoptosis through release of Smac/DIABLO, which
blocks inhibitor of apoptosis (IAP), and apoptosis induc-
ing factor (AIF) responsible for caspase-independent
apoptosis. Release of different pro-apotptotic factors is
regulated by Bcl-2 family proteins able to form homodi-
mers and heterodimers controlling mitochondrial mem-
brane permeability17. Some Bcl-2 family proteins (bcl-2,
bcl-x) block apoptosis while others (Bak, Bax, Bid) pro-
mote apoptosis. The intrinsic and extrinsic pathways are
linked in an amplification loop by Bid protein, cleaved by
caspase-8 to fragment (tBid), which translocates to the
mitochondria and triggers cytochrome-c release and acti-
vation of caspase-9. Activation of either of these up-
stream caspases leads to activation of terminal caspase-3
and caspase-7 leading to cell death17.
The balance between pro-apoptotic and anti-apoptotic
proteins has been shown to be disturbed in skin tumors
with pro-apoptotic proteins being reduced and anti-apo-
ptotic proteins being increased. Studies have detected de-
creased expression of pro-apoptotic bak and bax in BCC
and SCCand increased in KA4,18–20. On the other hand
anti-apoptotic bcl-2 and bcl-xL proteins expression were
found to be decreased or unaltered in SCC and actinic
keratosis and increased in BCC3,4,20.
The extrinsic pathway is stimulated by binding of
death ligands such as Fas ligand (Fas-L) and tumor ne-
crosis factor (TNF) to extracellular membrane »death re-
ceptor« that recruit adapter molecules and leads to acti-
vation of caspase-8, an subsequently a proteolytic casca-
de. Fas expression is weak in SCC and BCC that strongly
express FasL21–23. On the other hand KA has been shown
to consistently express high levels of Fas21.
Apoptosis Induced by UV Irradiation
Skin cells have the ability to repair UV-induced DNA
damage preventing skin carcinogenesis. Apoptosis of
cells damaged by UV irradiation is partly mediated by tu-
mor suppressor protein p53. Protein p53 is a well-de-
scribed tumor suppressor that has a central role in the
initiation of apoptosis and in cell cycle control24,25. Fol-
lowing acute UV light irradiation activation of p53 pro-
tein can arrest cell cycle at the G1 phase allowing extra
time for DNA repair or induces apoptosis of significantly
damaged cells. P53 protein protective function against
UV-light induced skin tumors is clearly determined in
mice models. On the other hand insufficient pre-carcino-
genic effect of clonal patches of p53-mutated keratino-
cytes10 suggests importance of p53-dependent and p53-
independent mechanisms in process of UV-light induced
carcinogenesis19.
Acute sun exposure mainly results in formation of
apoptotic cells, called sun-burn cells, in the epidermis
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while chronic sun exposure leads to accumulation of p53
gene mutations8,10,24,25. In contrast to acute chronic sun
exposure results in p53 gene mutation, p53 protein stabi-
lization and its increased expression as detected in ac-
tinic keratosis, Mb. Bowen, SCC, KA and sun exposed
normal skin4,26. p53 gene mutation results in loss of pro-
tective functions and development of pro-oncogenic func-
tions leading to uncontrolled cell proliferation and dis-
ability of cells to undergo apoptosis. Thus, resistance to
cell death is a key event in photocarcinogenesis and con-
versely, elimination of cells containing excessive UV-in-
duced DNA damage is a key step in protecting against
skin cancer development. Its critical role in maintaining
integrity of human genome is evident, because p53 is the
most commonly altered gene in human cancer (around
50% of human cancers) especially in NMSC3,25,26 and in
the majority of others its activity is blocked by increased
expression of different inhibitor or decreased activity of
co-activators24. p53 protein can induce apoptosis through
transcriptional and non-transcriptional mechanisms.
p53 tumor suppressor protein can influence both major
pathways of apoptosis, intrinsic and extrinsic24,27. p53
protein regulates apoptosis by disturbing the balance be-
tween pro-apoptotic and anti-apoptotic Bcl-2 family pro-
teins, up-regulating the Bak and Bax gene and down-reg-
ulating the Bcl-2 gene transcription. p53 also induces
apoptosis stimulating transcription of Fas and TRAIL-R
genes by binding to their transcriptional activation s-
ite28. It promotes the redistribution of cytoplasmic Fas to
the cell surface. Recent studies have shown that UV-in-
duced formation and »sun burn« cells are mediated by
p53 signaling through the Fas death receptor, which rap-
idly clusters following UVB exposure19. Studies on mice
models confirmed that FasL-mediated apoptosis is in-
volved in sun-burn cell formation since it is reduced in
mice deficient in Fas-L28.
UVB induces expression of multiple genes in kerati-
nocytes but also activation of pre-synthesized proteins.
Recently it has been shown that proapoptotic proteins
bak and bax also contribute to apoptosis following UV
exposure30. These proteins are expressed in healthy ke-
ratinocytes18,20 but are significantly up-regulated follow-
ing UV exposure30.
Although, UV exposure induces expression of differ-
ent genes important for activation of apoptosis, recent
studies have shown that UV irradiation also rapidly acti-
vates the epidermal growth factor receptor (EGFR)
which is highly mitogenic. Activation of EGFR favors
keratinocytes proliferation and suppresses apoptosis,
leading to epidermal hyperplasia31.
Other Factors Contributing to
Skin Cancer Development
Other factors, besides UV light, significantly contrib-
ute to the development of skin cancer especially in those
tumors developing in sun non-exposed areas. Newer stu-
dies showed the importance of co-carcinogenic effect of
Human papilloma viruses (HPV) and UV light mainly
through blockage of apoptosis. As mentioned earlier UV
light exposure leads to increased expression of p53 and
pro-apoptotic bak proteins that can than activate apo-
ptosis or result in cell cycle arrest. In the cells with mu-
tated p53 as in majority of skin cancers, bak protein can
activate apoptosis in p53-independent manner. Studies
have shown decreased expression of pro-apoptotic pro-
teins bak and bax in skin tumors, such as BCC and SCC,
and increased expression in KA4,18–20. It has been shown
that E6 protein HPV targets bak for degradation de-
creasing its expression in the cell and blocking UV-light
induced apoptosis19,30 favoring uncontrolled cell prolifer-
ation and tumor progression. Decreased bak expression
has been shown to correlate with worst tumor differenti-
ation and HPV positivity4,19,30.
Immunosupression, especially following transplanta-
tion, significantly increases risk for development of skin
cancers32. Increased incidence of skin cancer in immu-
nosupressed individuals is suggested to be the result of
co-carcinogenic effect of UV irradiation, through p53
gene mutation, and HPV19,30,32. Significantly higher inci-
dence of different HPV types was detected in SCCs (80%
positive tumors) in immunodeficient individuals as compa-
red to imunocompetent patients (30% positive SCCs)33.
Other physical factors such as irradiation and ther-
mal exposure as well as chemical carcinogens can con-
tribute to skin cancer development26,34. Skin cancers also
develop more often in chronic skin wound, on the site of
chronic trauma, chronic inflammation, degenerative skin
changes and different scars26,35.
UV-induced Immune Suppression
Contributes to Skin Cancer Development
and Progression
UV irradiation affects skin immune system. The skin
contains Langerhans cells that serve as antigen-present-
ing cells and serve to communicate with T cells. Also,
keratinocytes produce several cytokines that have a role
in immune recognition in the skin. These cells, together
with the regional draining lymph nodes, are labeled
»skin-associated lymphoid tissues« (SALT). UV irradia-
tion alters the morphology Langerhans cells, down-regu-
lates the expression of major histocompatibility complex
class II antigens on their surface and alters the cell-sur-
face expression of co-stimulatory molecules and intra-
cellular cell adhesion molecule 1. These changes block
the initiation of immune response. On the other, the sup-
pressive pathway is activated through formation of sup-
pressor T-cells36. Keratinocytes also release various cy-
tokines following UV irradiation, including interleukin 1
(IL-1), IL-4, IL-6, IL-10 and tumor necrosis factor alpha
(TNF-a)36. It has been shown that IL-10 has a central
role in the induction of both local and systemic immuno-
suppression following UV irradiation. It has been shown
that UV irradiation induces suppression of contact hy-
persensitivity and delayed-type hypersensitivity what
could favor development and growth of skin cancer.
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Anti-Tumor Immune Response and Tumor Escape
Mechanisms in Skin Cancer
Significance of the immune response in the control of
cutaneous SCC and KA is evident by increased risk of de-
velopment of cutaneous SCC in immunosuppressed in-
dividuals32 as well as T-cell infiltration within the lesions
of patients with cutaneous SCC and KA2,22,37,38. The role
of T cells in anti-tumor immunity is well established,
however, a tumor progression, often seen in the presence
of substantial lymphocyte infiltration, suggests that
these T cells are not capable of mounting an effective im-
mune response to control tumor growth38. Failure of tu-
mor-infiltrating lymphocytes to intervene and control tu-
mor growth is thought to be associated with signaling
dysfunction38, spontaneous apoptosis of circulating37–39
and tumor-infiltrating T lymphocytes22,38.
The immune system exerts its anti-tumor surveil-
lance and regression mainly through cell death induced
by cytotoxic CD8+ T lymphocytes (CTLs) and natural
killer (NK) cells supported by CD4+ T cells40,41. CTLs
can kill tumor cells and mediate tumor regression in vivo
through two distinct molecular mechanisms: one through
direct exocytosis of granules containing granzyme B and
perforin, and the other based on the binding of the CD95
(Fas) receptor on target cells40,41. Although it has been
suggested that in some tumors the FasL/Fas pathway is
important for optimal tumor regression40, tumor cells
are capable of developing different escape mechanisms in
order to overcome their sensitivity to apoptotic signals41.
CTLs may circumvent tumor resistance to Fas/FasL-in-
duced death via granzyme-mediated apoptosis42.
In the granzyme-mediated pathway, secreted lytic
protein perforin is believed to produce pores in the target
cell’s membrane and granzymes penetrate targeted cell
through these pores consequently inducing apoptosis41,42.
Other authors suggest that granzyme B, serine protease,
can be internalized into target cells independently of
perforin by receptor-mediated endocytosis36. Once deliv-
ered to the cytoplasm, granzyme B can induce apoptosis
in a few different pathways but it mainly utilizes mito-
chondrial pathway41. Also granzyme B can bypass mito-
chondria and cytochrome c release, by direct activation
of effector caspases and direct damage of non-nuclear
structures, such as mitochondria, in caspase-independ-
ent pathways41,43. Ability of granzyme B to bypass cas-
pase cascade and to activate apoptotic pathway at multiple
entry points is important, because of tumors capability to
develop different selective defects in the intracellular sig-
naling and caspase cascade leading to their resistance to
apoptotic stimuli41. It has been shown that granzyme
B/perforin pathway can kill tumor cells in vitro and is
able to induce apoptosis in multiple-drug-resistant and
death-receptor resistant cell lines44, although some stud-
ies suggested that tumors can resist granzyme-mediated
killing through overexpression of the protease inhibitor
PI-9/SPI-6 (serpin) 45.
Tumor cells are capable of developing different escape
mechanisms in order to overcome their sensitivity to
apoptotic signals41. SCC can escape Fas/FasL mediated
killing by down-regulating Fas expression on the cell
surface21, and mediate killing of infiltrating T lympho-
cytes by expressing FasL on their surface38,40,43,46. On the
other hand KAs have been shown to consistently express
high levels of Fas at the interface with the inflammatory
cells, being susceptible to T-cell mediated apoptosis con-
tributing to tumor regression21.
Recent studies suggested significance of the intensity
of inflammatory infiltrate, the number of cytotoxic
CD8+ T cells and increased cytotoxic activity as deter-
mined by granzyme B expression in skin tumors growth
and regression control6,47. Granzyme B expression has
been found to be significantly increased in KAs as com-
pared with SCCs and was suggested to contribute to KA
regression6. Even though CD8+ cytotoxic T lymphocytes
appear to be critical for causing tumor regression, it has
been suggested that the quantity of these cells alone is
not sufficient38.
Accumulating evidence suggests that T lymphocytes
infiltrating human neoplasms are functionally defective,
incompletely activated or anergic. Recent studies suggest
that tumor regression and anti-tumor protective res-
ponse depends mainly on immune response mediated by
cytotoxic CD8+ T lymphocytes supported by CD4+ T
cells producing IFN-gamma33. T helper type 1 (Th1)
CD4+ anti-tumor T cell secreting IFN-gamma appears
crucial to the optimal induction and maintenance of du-
rable anti-tumor CTL responses in vivo and may serve to
recruit these effector cells into the tumor microenvi-
ronment via delayed-type hypersensitivity responses48.
In contrast, T helper type 2 (Th2) or T helper type 3
(Th3) CD4+ T cell responses may subvert Th1-type cell-
mediated immunity, providing a microenvironment con-
ducive to disease progression. Studies on melanoma mo-
del have detected a gradual shift of initial Th0-type,
mixed Th1-/Th2-type CD4+ T cell response to Th2-type
dominated responses with progressive tumor growth49. It
has been shown that tumor infiltrating lymphocytes in
patients with spontaneous and therapeutically induced
regressing lesions appear to be characterized by domi-
nant Th1-type responses to mitogens, whereas tumor in-
filtrating lymphocytes from patients with progressing le-
sions have been reported to exhibit functionally domi-
nant Th2-type (IL-4, IL-5) and/or Th3-/Tr-type (IL-10,
TGF-ß1) CD4+ T cell responses50.
Apoptosis of tumor infiltrating T lymphocytes ob-
served in situ was suggested to be related to expression
of FasL and perhaps other death-related molecules on
the tumor cell surface since immunostaining indicated
that FasL+ tumors were often infiltrated by Fas+ lym-
phocytes, many showing evidence of apoptosis22,37,38.
Apoptosis of tumor infiltrating T cells can result in de-
creased T cell density favoring tumor progression22,37,38.
Previously described presence of the unusual CD3+
CD4-CD8- phenotype attributed to apoptosis51 of tumor
infiltrating lymphocytes in strong FasL expressing tu-
mors, such as SCC and BCC23, has been detected in rare
cases of KAs and majority of SCCs38.
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Role of Telomerase in Skin Cancer
Telomeres are specialized structures at the ends of
eukaryotic chromosomes that play a central role in chro-
mosome protection, positioning and replication. Telome-
rase is a ribonucleoprotein reverse transcriptase that
synthesizes telomeric DNA onto chromosomal ends pro-
tecting chromosomes from degradation. As the normal
cell divides, there is a corresponding shortening of telo-
meres, thus acting as mitotic clock by which cells count
their divisions. Finally, chromosomes reach a critical
length at which cell division ceases, senescence begins,
and the cell ultimately undergoes apoptosis or cell
death52,53. Telomerase activity presents a critical step in
tumorigenesis because it overcomes the limitations of
catastrophic telomere loss and is actually present in
more than 80% of human cancer including skin can-
cers53,54,55. Telomerase activity is detectable in germline
cells, somatic cells during fetal development, germinal
centers of lymph nodes, regenerative epithelium of the
gastrointestinal tract, proliferative endometrium, the
bulge region of hair follicles, and stem cells of epider-
mis56–59. Studies have shown that sun-damaged skin has
a higher telomerase activity than sun-protected areas, al-
though much less than that detected in non-melanoma
and melanoma skin tumors, suggesting that environ-
mental factors may modulate telomerase expression60.
Increased telomerase activity has been suggested to cor-
relate with the progression of benign melanocytic through
dysplastic lesion to malignant melanoma55. The signifi-
cant role of telomerase in skin cancer development and
progression is evident in significantly higher activity de-
tected in SCC as compared to KA61.
Future Challenges and Directions
In the past thirty years since first description of
apoptosis, intense studies acquired significant under-
standing of the molecular controls and biochemical pro-
cesses involved in programmed sell death in healthy skin
and various skin diseases. The role of keratinocyte apo-
ptosis is better understood in epidermal development.
Further studies should be directed toward unraveling
completely the details of apoptotic control in normal skin
and further understanding of factors resulting in apo-
ptotic disbalance and disease. Also, there is a need for
further research to study the molecular mechanisms in-
volved in tumor regression, spontaneous and therapy in-
duced. The new knowledge should be used in develop-
ment of new apoptosis-based therapeutics, directed
toward protection of keratinocytes, in diseases character-
ized by intense cell death, or enhancement of apoptosis,
in diseases characterized by impaired cell death. Al-
though a wide range of inflammatory and hyperkeratotic
diseases might be treated with apoptosis-based thera-
pies, there appears to be the greatest interest in develop-
ing agents for cancers therapy.
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APOPTOZA U NASTANKU I REGRESIJI TUMORA KO@E
S A @ E T A K
Epitelni tumori ko`e naj~e{}i su tumori bijele populacije i njihova je incidencija u konstantnom porastu u svijetu.
Molekularni mehanizmi bitni u regulaciji pre`ivljavanja, apoptoze, zaustavljanja rasta i diferencijacije stanica dopri-
nose kinetici rasta stanica, te imaju sredi{nju ulogu u nastanku, progresiji i regresiji benignih i malignih tumora ko`e.
Neadekvatna funkcija ovih mehanizama mo`e uzrokovati gubitak kontrole proliferacije stanica uz posljedi~ni razvoj
tumora inaktivacijom tumor-supresorskih gena ili aktivacijom onkogena. Imunolo{ki mehanizmi, tako|er, imaju bitnu
ulogu u procesu progresije i regresije tumora. U radu su sa`eto prikazana osnovna zbivanja bitna u etiopatogenezi,
razvoju, progresiji, te ponekad spontanoj regresiji tumora ko`e. Dodatne studije potrebne su kako bi se u potpunosti
razjasnio kompleksan proces programirane smrti stanice u zdravom tkivu i utvrdili ~imbenici koji uzrokuju poreme}aje
ovog procesa i maligni rast stanica.
T. Batinac et al.: Apoptosis in skin cancer, Coll. Antropol. 31 (2007) Suppl. 1: 23–28
28
U:\coll-antropolo\coll-antro-suppl-1-2007\batinac 2.vp
9. veljaŁa 2007 12:35:03
Color profile: Disabled
Composite  150 lpi at 45 degrees
